Press releases
- Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
- Fulgent Reports First Quarter 2024 Financial Results
- Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
More ▼
Key statistics
On Wednesday, Fulgent Genetics Inc (7F0:FRA) closed at 18.50, 10.12% above the 52 week low of 16.80 set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.50 |
---|---|
High | 18.50 |
Low | 18.50 |
Bid | 18.40 |
Offer | 18.70 |
Previous close | 18.60 |
Average volume | 14.44 |
---|---|
Shares outstanding | 29.92m |
Free float | 20.18m |
P/E (TTM) | -- |
Market cap | 597.89m USD |
EPS (TTM) | -5.57 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:00 BST.
More ▼